this point well in their Table 1 , which reported differences across studies in the measures of direct cost, and differences in methods for calculating indirect costs including not calculating them [2] .
Economists will caution against using cost-of-illness studies to prioritize diseases on which to intervene or interventions to adopt. The results are at best the maximum amount that could be saved. Costeffectiveness analysis, which is the ratio of cost to health outcomes, is more widely accepted, because researchers can systematically calculate the cost of an intervention net of the cost-of-illness saved, and the health outcomes gained. For example, treatment with anti-epileptic drugs in a primary care setting had some of the lowest cost per disability-adjustedlife year averted in Sub-Saharan Africa in a comparison of strategies to reduce the burden of neuropsychiatric conditions [10] .
Fodjo and colleagues wisely acknowledge that their estimate of the economic burden of epilepsy is the first step towards conducting costeffectiveness analyses of interventions such as improved access to treatment for epilepsy at health centers [2] . In the Democratic Republic of Congo and similar settings, a proportion of epilepsy is due to infectious and neonatal causes, suggesting that interventions such as improving hygiene and sanitation that would reduce the incidence of neurocysticercosis and cystic echinococcosis, as well as reducing transmission and improving control of onchocerciasis, should also be evaluated. Their ongoing research will help to answer the question posed in our title.
